IV KETAMINE THERAPY CLINIC BUSINESS PLAN
Â
I. Executive Summary
Company Description
The clinic launches in 2026 as a specialized medical practice providing IV ketamine infusion therapy for treatment-resistant mental health conditions and chronic pain. It operates in the U.S. interventional psychiatry and pain-management sector. Core services are physician-supervised IV ketamine infusions administered by an Anesthesiologist and Psychiatric Nurse Practitioners in a serene, medicalized setting that combines advanced monitoring equipment with a patient-centered care model. Main activities include patient evaluation, individualized infusion protocols, peri-infusion monitoring, medication management, and coordinated follow-up with referring mental health providers. One-line: high-efficacy, rapid-acting medical treatment delivered under direct specialist supervision.
The clinic targets adults with treatment-resistant depression, PTSD, bipolar-spectrum depressive episodes, and chronic neuropathic or centralized pain who seek fast clinical response and are appropriate for interventional care. Competitive advantages include direct Anesthesiologist oversight, integrated psychiatric NP protocols, medical-grade monitoring, and a sanctuary-like patient experience focused on safety and comfort. Short-term goals are to open in 2026, complete 400 infusions in year one, and establish 30 referral sources locally. Long-term goals are regional leadership in interventional psychiatric services, standardized outcome tracking, and expansion to a second location within 3–5 years. One-line: build measurable clinical outcomes and scalable, specialist-led care pathways.
Â
Problem
Millions of Americans live with treatment-resistant depression (TRD) and chronic pain where standard oral medications and psychotherapy have failed, producing persistent functional loss and reduced quality of life.
There is an urgent gap in the 2026 U.S. healthcare landscape: rapid-acting, evidence-based interventions are scarce for Major Depressive Disorder, PTSD, complex regional pain syndrome (CRPS), and fibromyalgia.
Consequences include loss of work capacity and income, reliance on long-term opioids or polypharmacy, higher suicide and hospitalization risk, long waitlists for specialty care, and inadequate symptom relief—all of which existing standard treatments do not reliably resolve.
Â
Solution
Millions of Americans with treatment-resistant depression, PTSD, and chronic pain lack effective, fast-acting options and specialized, safe clinics. We provide medically supervised intravenous ketamine infusion therapy in a serene, medically controlled clinic with a multidisciplinary team, continuous physiological monitoring, integrated psychological support, credentialed staff, and private treatment rooms to fill that gap.
Protocol: an initial induction of six infusions over two weeks, then maintenance booster infusions as needed, enabling rapid symptom relief, transition to monthly boosters plus therapy, and reduced emergency visits and medication burden.
Â
Mission Statement
Our mission is to deliver safe, compassionate, evidence-based ketamine therapy in a medically controlled setting to restore quality of life for people with severe mental health and chronic pain when traditional treatments have failed. We commit to clinical excellence, personalized care, measurable outcomes, and advancing interventional psychiatry to set the standard for patient safety and rapid healing.
Â
Key Success Factors
These facts drive our clinic’s rapid growth and durable market position.
-
Elite clinical team led by an Anesthesiologist Medical Director ensures highest safety standards.
-
Two-month breakeven demonstrates strong demand and efficient unit economics.
-
High-growth revenue trajectory rising from $1.3M to $9.2M in five years.
-
Serene, specialized facility offers a clear competitive advantage over hospital-based treatments.
-
Strong referral network with local mental health professionals provides a steady pipeline of qualified patients.
Financial Summary
Financial summary for the Executive Summary: year-one revenue is projected at $1,327,000 with breakeven in February 2026 and full payback in 21 months.
Â
Ratio |
2026 |
2027 |
2028 |
Projected Revenue |
$1,327,000 |
$2,631,000 |
$4,098,000 |
Projected EBITDA |
$34,000 |
$741,000 |
$1,700,000 |
Expected ROI |
IRR 9.49% |
IRR 9.49% |
IRR 9.49% |
Â
Financial requirements: minimum cash buffer of $657,000; expected project IRR 9.49% and ROE 11.45%; breakeven in Feb-2026 and payback in 21 months.
The financial outlook is positive: revenue grows from $1.3M in 2026 to $9.252M by 2030 with EBITDA reaching $5.214M in 2030.
Â
Funding Requirements
USD 992,000 is required to launch in 2026; projected first-year revenue is USD 1,327,000, breakeven is February 2026, full payback in 21 months, IRR 9.49 percent, and ROE 11.45 percent.
Â
Categories |
Amount, USD |
Clinic buildout and medical equipment (CapEx) |
335,000 |
DEA and state licensing |
 |
Initial hiring and onboarding (7 employees) |
 |
Initial operating losses (first two months) |
 |
Administrative setup and IT security |
 |
Marketing and referral outreach (launch) |
 |
Contingency reserve |
 |
Working capital |
657,000 |
Total funding required |
992,000 |
Â